177 related articles for article (PubMed ID: 17277931)
1. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.
Fortin MA; Salnikov AV; Nestor M; Heldin NE; Rubin K; Lundqvist H
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1376-87. PubMed ID: 17277931
[TBL] [Abstract][Full Text] [Related]
2. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
[TBL] [Abstract][Full Text] [Related]
3. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
Verel I; Heider KH; Siegmund M; Ostermann E; Patzelt E; Sproll M; Snow GB; Adolf GR; van Dongen GA
Int J Cancer; 2002 May; 99(3):396-402. PubMed ID: 11992408
[TBL] [Abstract][Full Text] [Related]
5. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice.
van Gog FB; Brakenhoff RH; Snow GB; van Dongen GA
Cancer Immunol Immunother; 1997 Apr; 44(2):103-11. PubMed ID: 9177472
[TBL] [Abstract][Full Text] [Related]
6. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
7. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma.
Lammerts E; Roswall P; Sundberg C; Gotwals PJ; Koteliansky VE; Reed RK; Heldin NE; Rubin K
Int J Cancer; 2002 Dec; 102(5):453-62. PubMed ID: 12432546
[TBL] [Abstract][Full Text] [Related]
8. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
9. The use of closo-dodecaborate-containing linker improves targeting of HNSCC xenografts with radioiodinated chimeric monoclonal antibody U36.
Cheng J; Engstrom M; Ekberg T; Nestor M; Anniko M; Tolmachev V
Mol Med Rep; 2010; 3(1):155-60. PubMed ID: 21472215
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods.
Nestor M; Persson M; Cheng J; Tolmachev V; van Dongen G; Anniko M; Kairemo K
Bioconjug Chem; 2003; 14(4):805-10. PubMed ID: 12862434
[TBL] [Abstract][Full Text] [Related]
11. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
12. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.
Sandström K; Haylock AK; Spiegelberg D; Qvarnström F; Wester K; Nestor M
Int J Oncol; 2012 May; 40(5):1525-32. PubMed ID: 22307465
[TBL] [Abstract][Full Text] [Related]
13. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
[TBL] [Abstract][Full Text] [Related]
14. Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.
Nestor M; Ekberg T; Dring J; van Dongen GA; Wester K; Tolmachev V; Anniko M
Tumour Biol; 2007; 28(5):253-63. PubMed ID: 17992053
[TBL] [Abstract][Full Text] [Related]
15. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody.
Sandström K; Nestor M; Ekberg T; Engström M; Anniko M; Lundqvist H
Tumour Biol; 2008; 29(3):137-44. PubMed ID: 18612218
[TBL] [Abstract][Full Text] [Related]
17. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]